Close Menu

NEW YORK (GenomeWeb) – KellBenx, a Great River, New York-based firm  developing technology that can identify fetal cells in maternal blood,  is about to launch a 1,000-person clinical validation study in collaboration with Columbia University with the hopes of subsequently commercializing a noninvasive prenatal diagnostic based on the technology.

According to KellBenx CEO Hassan Bennani, tests that analyze these fetal cells could be more accurate than those that analyze cell-free fetal DNA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Independent advisors to the US Food and Drug Administration are to meet this week to discuss how they will make SARS-CoV-2 vaccine recommendations, the Washington Post reports.

The New York Times reports on how the US Food and Drug Administration has attempted to gird against pressure from the White House.

Researchers have identified a gene involved in how people determine when to urinate.

In Genome Research this week: assay for profiling chromatin accessibility, analysis of genetic variants among malaria-transmitting mosquitoes, and more.